ARIC Neurocognitive Study (ARIC-NCS) Renewal 1 of 5 Johns Hopkins Washington County Field Center Principal Investigator (Josef Coresh, MD, PhD). Rationale: Dementia and mild cognitive impairment (MCI) pose a large and increasing health and societal burden on the aging US population and ARIC is uniquely suited to contribute critical information on the vascular, and potentially preventable, contributions to dementia and MCI incidence. Progress: ARIC NCS (Visit 5: 2011-13) measured a battery of cognitive tests on ARIC participants aged 70- 89 and all study goals were met or exceeded, completing 6,538 exams, 2009 MRIs (520 in African-Americans) with a large number of dementia and Mild Cognitive Impairment (MCI) cases currently being adjudicated. Early papers were submitted within a month of completion of data collection and promising work is ongoing (~50 manuscript proposals). Collection of cognitive decline in late-life is needed and time sensitive since the cohort is experiencing ~5% annual mortality (mean age 78 years). Design: Follow-up cognitive testing (~30-year f/u, 2015-2018), at ages where cognitive decline begins to manifest across several domains or accelerates, thus providing many additional, diverse outcomes in the ARIC cohort (15,792 men and women ages 45-65 recruited in 1986-1989 and followed with detailed examinations). Outcomes: The late life cognitive outcomes targeted in the renewal differ from the one-time static measures of cognitive performance now available from the ARIC NCS baseline exam. A. Decline in global cognitive ability, executive function/processing speed, memory, and language - assessed during in ~4214, ~4 years after V5 (more comprehensive than possible in previous visits which had a more limited 3 test battery similar to older cardiovascular studies; 2nd visit in oldest subset). B. Incidence of MCI and dementia - detect ~1,521 dementia 1,134 MCI incident cases using procedures established after NCS V5 (2011-2013; expanded ARIC's semi-annual calls; response rate ~90%). C. Progression from MCI to dementia - following the 1,402 MCI cases identified at V5.
Aims : We will study a wealth of modifiable vascular risk factors and measures of microvascular disease and atherosclerosis in midlife, many not available in other studies of cognition, for their contribution to late life cogntive decline and physical function. We will study the detailed 3T brain MRI imaging at visit 5 as a risk factor for cognitive decline at older age. We will determine if any of these associations are different in African- Americans, where longitudinal cognitive data are nearly non-existent and vascular burden is high, than in white ARIC participants. We will share these data all ARIC ancillaries (Appendix 4), including detailed genetic and biochemical studies across the lifespan. Summary: This NCS visit (V6: 2015-2018; V7: 2017-2018 in oldest subset) will advance knowledge about the potentially modifiable vascular contribution to cognitive decline in late life and provide the cornerstone for other synergistic ancillary studies by a large community of investigators which would not otherwise be possible.

Public Health Relevance

ARIC-NCS renewal (2015-2018) will study cognitive decline at old age and the transition from mild-cognitive impairment to dementia. It builds on the initial phase of the study (2010-2014) which related midlife risk factors (measured at age 45-65 years) to cognitive decline over the next 25 years when detailed data was collected on cognition, cardiovascular status on 6500 people with brain MRI data on 2,000 individuals. This proposal will follow all individuals for incidence of mild cognitive impairment (MCI) and dementia and include an examination of 4214 individuals. The public health relevance is evident given the growing magnitude of dementia and mild cognitive impairment, the realization of a strong association with vascular disease, and the reasonable assumption that the risk of dementia and mild cognitive impairment, like strokes, can be substantially reduced by risk factor modification.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HL096917-06
Application #
9134805
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Wright, Jacqueline
Project Start
2010-07-07
Project End
2019-06-30
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
6
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Mississippi Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
928824473
City
Jackson
State
MS
Country
United States
Zip Code
39216
Witt, Lucy S; Rotter, Jason; Stearns, Sally C et al. (2018) Heart Failure and Cognitive Impairment in the Atherosclerosis Risk in Communities (ARIC) Study. J Gen Intern Med 33:1721-1728
Walker, Keenan A; Windham, B Gwen; Power, Melinda C et al. (2018) The association of mid-to late-life systemic inflammation with white matter structure in older adults: The Atherosclerosis Risk in Communities Study. Neurobiol Aging 68:26-33
Power, Melinda C; Rawlings, Andreea; Sharrett, A Richey et al. (2018) Association of midlife lipids with 20-year cognitive change: A cohort study. Alzheimers Dement 14:167-177
Lee, Alexandra K; Rawlings, Andreea M; Lee, Clare J et al. (2018) Severe hypoglycaemia, mild cognitive impairment, dementia and brain volumes in older adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) cohort study. Diabetologia 61:1956-1965
Knopman, David S; Gottesman, Rebecca F; Sharrett, A Richey et al. (2018) Midlife vascular risk factors and midlife cognitive status in relation to prevalence of mild cognitive impairment and dementia in later life: The Atherosclerosis Risk in Communities Study. Alzheimers Dement 14:1406-1415
Lutsey, Pamela L; Misialek, Jeffrey R; Mosley, Thomas H et al. (2018) Sleep characteristics and risk of dementia and Alzheimer's disease: The Atherosclerosis Risk in Communities Study. Alzheimers Dement 14:157-166
Norby, Faye L; Chen, Lin Y; Soliman, Elsayed Z et al. (2018) Association of left ventricular hypertrophy with cognitive decline and dementia risk over 20 years: The Atherosclerosis Risk In Communities-Neurocognitive Study (ARIC-NCS). Am Heart J 204:58-67
Wennberg, Alexandra M V; Hagen, Clinton E; Machulda, Mary M et al. (2018) The association between peripheral total IGF-1, IGFBP-3, and IGF-1/IGFBP-3 and functional and cognitive outcomes in the Mayo Clinic Study of Aging. Neurobiol Aging 66:68-74
González, Hector M; Tarraf, Wassim; Harrison, Kimystian et al. (2018) Midlife cardiovascular health and 20-year cognitive decline: Atherosclerosis Risk in Communities Study results. Alzheimers Dement 14:579-589
Deal, Jennifer A; Goman, Adele M; Albert, Marilyn S et al. (2018) Hearing treatment for reducing cognitive decline: Design and methods of the Aging and Cognitive Health Evaluation in Elders randomized controlled trial. Alzheimers Dement (N Y) 4:499-507

Showing the most recent 10 out of 135 publications